Rosmarinic acid and cognition
What 3 graded rows on rosmarinic acid agree on for cognition, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Rosmarinic acid page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Rosmarinic acid page, with its PubMed record.
Your question
Rosmarinic acid and cognition
3 rows · 436 peopleSplit. 1 row found an improvement, 1 found no difference and 1 had mixed results.
- CGrade C× 1
- DGrade D× 2
- Rows
- 3
- Trials
- 3
- People
- 436
Where they differ
From the rowsThe best-graded row, grade C, is a randomized trial of 323 people (2023) and found no difference.
The row that found no difference was larger: 323 people, against 90 people for the row that found an improvement.
The row that found no difference ran longer (22 months) than the row that found an improvement (3 months).
Only the row that found no difference names older adults in its population.
The row that found no difference is newer (2023) than the row that found an improvement (2018).
The best grade is C among the row that found no difference, and D among the row that found an improvement.
1 row with mixed results is left out of this comparison.
The rows
1 improved · 1 no difference · 1 mixed- DGrade DWorking memory and sleep onset in age-associated memory impairment · Improved
RCT · n 90 · 2018 · Adults with age-associated memory impairment, mean age 59 (USA)
600 or 900 mg/day of extract · 90 days
At 900 mg/day, quality of working memory improved 15% and spatial working memory accuracy 9% versus placebo, and people reported falling asleep more easily; 600 mg/day was not reported as significant for these outcomes.
Row on the Rosmarinic acid page · PubMed 29314866 (opens PubMed)
- CGrade CCognitive decline in older adults without dementia · No difference
RCT · n 323 · 2023 · Older adults with subjective or mild cognitive impairment (Japan)
500 mg/day rosmarinic acid · 96 weeks plus 24-week washout
No differences in ADAS-cog or other cognitive measures versus placebo at 96 weeks. An exploratory analysis limited to participants without hypertension found a statistically significant difference in CDR Sum of Boxes (p = 0.036), which the authors read as a possible benefit.
Row on the Rosmarinic acid page · PubMed 36502333 (opens PubMed)
- DGrade DSafety, cognition and behaviour in mild Alzheimer's dementia · Mixed
RCT · n 23 · 2020 · Patients with mild dementia due to probable Alzheimer's disease (Japan)
500 mg/day rosmarinic acid · 24 weeks
Safe and well tolerated (primary endpoint). Cognitive scores did not differ; the neuropsychiatric NPI-Q score improved 0.5 points versus a 0.7-point worsening on placebo (P = 0.012).
Row on the Rosmarinic acid page · PubMed 33122694 (opens PubMed)